Pricing Log in Create free account

Corcept Therapeutics Incorporated (CORT) vs Halozyme Therapeutics, Inc. (HALO)

Corcept Therapeutics Incorporated and Halozyme Therapeutics, Inc. are both Biotechnology companies. Halozyme Therapeutics, Inc. is the larger, with a market value of $13.8B against $12.3B — 1.1× the size. Halozyme Therapeutics, Inc. trades at the lower P/E: 34.6× against 212×. Halozyme Therapeutics, Inc. grew revenue faster over the last twelve months: 41.2% against 16.0%. Halozyme Therapeutics, Inc. has the higher net margin (24.9% vs 6.53%) and the higher return on invested capital (18.1% vs 1.01%). Across the 22 metrics below, Halozyme Therapeutics, Inc. leads on 17 and Corcept Therapeutics Incorporated on 5.

Valuation

Metric CORT HALO Biotechnology median
P/E 211.85 34.61 8.50
P/S 13.97 8.59 9.71
P/B 16.45 99.54 2.13
Price to free cash flow 108.57 17.72 20.82
EV/EBITDA 3,040.10 22.53 0.64
EV/Sales 13.62 9.74 9.21
Earnings yield 0.47% 2.89% (33.15%)
Free cash flow yield 0.92% 5.64% (25.50%)

Profitability

Metric CORT HALO Biotechnology median
Gross margin 98.30% 82.42% 65.16%
Operating margin 0.77% 35.90% 0.00%
Net margin 6.53% 24.86% 0.00%
Free cash flow margin 12.87% 48.46% 0.00%
Return on equity 8.08% 173.67% (56.36%)
Return on assets 6.41% 17.86% (48.04%)
Return on invested capital 1.01% 18.13% 0.00%

Growth

Metric CORT HALO Biotechnology median
Revenue growth (TTM) 16.02% 41.15% 6.02%
EPS growth (last fiscal year) (33.33%) (25.36%) 30.26%
Revenue growth, 5-year CAGR 16.56% 39.16% 9.41%
Net income growth, 5-year CAGR (1.52%) 19.68% 0.00%

Health

Metric CORT HALO Biotechnology median
Debt to equity 0.00 14.95 0.00
Current ratio 2.86 2.71 4.72
Net debt to EBITDA (8.83) 3.56 0.96

Dividend

Metric CORT HALO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CORT HALO Biotechnology median
Market cap 12.26b 13.79b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack